WO2022242752A1 - 一种btk抑制剂中间体的制备方法 - Google Patents

一种btk抑制剂中间体的制备方法 Download PDF

Info

Publication number
WO2022242752A1
WO2022242752A1 PCT/CN2022/094153 CN2022094153W WO2022242752A1 WO 2022242752 A1 WO2022242752 A1 WO 2022242752A1 CN 2022094153 W CN2022094153 W CN 2022094153W WO 2022242752 A1 WO2022242752 A1 WO 2022242752A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound shown
preparation
protecting group
compound
Prior art date
Application number
PCT/CN2022/094153
Other languages
English (en)
French (fr)
Inventor
吕先宇
陈亚
王入志
张磊
郭昌山
Original Assignee
江苏恒瑞医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏恒瑞医药股份有限公司 filed Critical 江苏恒瑞医药股份有限公司
Priority to CN202280036495.6A priority Critical patent/CN117355513A/zh
Publication of WO2022242752A1 publication Critical patent/WO2022242752A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the disclosure belongs to the field of medicine, and relates to a preparation method of a BTK inhibitor intermediate.
  • Immune cells can usually be divided into T cells and B cells.
  • the main function of B cells is to secrete various antibodies to help the body resist various foreign invasions.
  • Bruton's tyrosine protein kinase (BTK) is one of the members of the tyrosine protein kinase subfamily and belongs to the Tec family of kinases. It is mainly expressed in B cells and distributed in the lymphatic system, hematopoietic and blood systems.
  • B-cell receptor for subtypes including chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL)
  • CLL chronic lymphocytic leukemia
  • NHL non-Hodgkin's lymphoma
  • MCL mantle cell lymphoma
  • DLBCL diffuse large B-cell lymphoma
  • BTK Bruton's tyrosine kinase
  • BTK is a key protein kinase in the BCR signaling pathway. It can regulate the maturation and differentiation of normal B cells, and is also closely related to a variety of B cell lymphoid tissue disorders. Therefore, targeting small-molecule inhibitors of BTK may provide benefits in the treatment of B-cell malignancies and autoimmune diseases.
  • WO2016007185A1 relates to a compound represented by formula (I), namely (R)-4-amino-1-(1-(but-2-ynoyl)pyrrolidin-3-yl)-3-(4-(2, 6-difluorophenoxy)phenyl)-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one, the compound is a new type of BTK kinase inhibitor, in kinase selective , clinical efficacy or indications, and safety have been improved, and its structure is as follows:
  • WO2016007185A1 also discloses a compound represented by formula (A), which is an important intermediate for preparing the compound of formula (I).
  • the yield and purity of the compound shown in formula (A) directly affect the product quality of subsequent compounds.
  • the purpose of this disclosure is to provide a new preparation method of BTK inhibitor intermediate.
  • the present disclosure also provides a method for preparing the compound shown in formula (A'K), including the steps of preparing the compound shown in formula (IIK) from the compound shown in formula (IIIK), and preparing the compound shown in formula (IIK) The steps of the compound shown in (A'K),
  • R is selected from a hydrogen atom or a carboxyl protecting group, preferably a carboxyl protecting group, more preferably a C 1-6 alkyl group;
  • R is selected from a hydrogen atom or an amino protecting group, preferably an amino protecting group, more preferably tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl and benzenesulfonyl;
  • R is selected from a hydrogen atom or an amino protecting group, preferably an amino protecting group, more preferably tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl and benzenesulfonyl;
  • R is selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, 3 to 8 membered cycloalkyloxy, 3 to 8 membered heterocyclyloxy, 6 to 10 membered aryloxy and 5 to 10 membered heteroaryloxy, the C 1-6 alkyl, C 1-6 alkoxy, 3 to 8 membered cycloalkyloxy, 3 to 8 membered heterocyclyloxy, 6 to 10-membered aryloxy and 5 to 10-membered heteroaryloxy are optionally substituted by one or more substituents selected from halogen, C 1-6 alkyl and C 1-6 alkoxy;
  • n is selected from 0, 1, 2, 3, 4 and 5.
  • the present disclosure provides a method for preparing a compound represented by formula (A'G), comprising the steps of preparing a compound represented by formula (IIG) from a compound represented by formula (IIIG), and formula (IIG ) compound shown in the steps of preparing the compound shown in formula (A'G),
  • R is selected from a hydrogen atom or a carboxyl protecting group, preferably a carboxyl protecting group, more preferably a C 1-6 alkyl group;
  • R is selected from a hydrogen atom or an amino protecting group, preferably an amino protecting group, more preferably tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl and benzenesulfonyl;
  • R is selected from a hydrogen atom or an amino protecting group, preferably an amino protecting group, more preferably tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl and benzenesulfonyl;
  • R is selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, 3 to 8 membered cycloalkyloxy, 3 to 8 membered heterocyclyloxy, 6 to 10 membered aryloxy and 5 to 10 membered heteroaryloxy, the C 1-6 alkyl, C 1-6 alkoxy, 3 to 8 membered cycloalkyloxy, 3 to 8 membered heterocyclyloxy, 6 to The 10-membered aryloxy group and the 5- to 10-membered heteroaryloxy group are optionally substituted with one or more substituents selected from halogen, C 1-6 alkyl and C 1-6 alkoxy.
  • the compound shown in formula (IIIK) and the compound shown in formula (III-1) are prepared under the condition that the compound shown in formula (IIK) exists in alkaline reagent, and formula (III-1) is X is halogen.
  • the compound shown in formula (IIIG) and the compound shown in formula (III-1) are prepared under the condition that the compound shown in formula (IIG) exists under the condition of alkali reagent, and formula (III-1) is X is halogen.
  • the compound shown in formula (IIIK) and the compound shown in formula (III-1) are prepared under the condition that the compound shown in formula (IIK) exists in alkaline reagent, and formula (III-1) is X is a halogen, and the alkaline reagent is selected from common format reagents such as lithium diisopropylamide (LDA), butyllithium, and isopropylmagnesium chloride.
  • LDA lithium diisopropylamide
  • butyllithium butyllithium
  • isopropylmagnesium chloride isopropylmagnesium chloride.
  • the compound shown in formula (IIIG) and the compound shown in formula (III-1) are prepared under the condition that the compound shown in formula (IIG) exists under the condition of alkali reagent, and formula (III-1) is X is a halogen, and the alkaline reagent is selected from common format reagents such as lithium diisopropylamide (LDA), butyllithium, and isopropylmagnesium chloride.
  • LDA lithium diisopropylamide
  • butyllithium butyllithium
  • isopropylmagnesium chloride isopropylmagnesium chloride.
  • X is chlorine
  • the base reagent is lithium diisopropylamide.
  • the present disclosure also provides a method for preparing the compound shown in formula (A'), including the steps of preparing the compound shown in formula (II) from the compound shown in formula (III), and preparing the compound shown in formula (II) from the compound shown in formula ( The step of the compound shown in A'),
  • R is selected from a hydrogen atom or a carboxyl protecting group, preferably a carboxyl protecting group, more preferably a C 1-6 alkyl group;
  • R is selected from a hydrogen atom or an amino protecting group, preferably an amino protecting group, more preferably tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl and benzenesulfonyl;
  • R 3 is selected from a hydrogen atom or an amino protecting group, preferably an amino protecting group, more preferably tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl and benzenesulfonyl.
  • the compound shown in formula (II) is prepared from the compound shown in formula (III) and the compound shown in formula (III-1) in the presence of a base reagent, X is a halogen, preferably chlorine, and the base
  • a base reagent preferably lithium diisopropylamide (LDA), butyllithium, isopropylmagnesium chloride and other common Grignard reagents, among which lithium diisopropylamide is more preferred.
  • the molar ratio of the compound represented by the formula (III) to the lithium reagent is 1:0.1 to 1:10, preferably 1:1 to 1:5, more preferably 1:1 to 1:3 .
  • the molar ratio of the compound represented by formula (III) to the compound represented by formula (III-1) is 1:0.1 to 1:10, preferably 1:1 to 1:5, more preferably 1:1 ⁇ 1:3.
  • the reaction temperature is -100 to -30°C, preferably -85 to -65°C.
  • R 3 is an amino protecting group, the method further comprising
  • R 1 , R w and n are as defined in formula (IIK).
  • R 3 is an amino protecting group, the method further comprising
  • R 1 and R w are as defined in formula (IIG).
  • R is halogen or phenyloxy
  • said phenyl is optionally substituted by one or more of halogen, C 1-6 alkyl and C 1-6 alkoxy base substitution.
  • Rw is halogen
  • R is selected from a hydrogen atom or a carboxyl protecting group, preferably a carboxyl protecting group, more preferably a C 1-6 alkyl group;
  • R is selected from a hydrogen atom or an amino protecting group, preferably an amino protecting group, more preferably tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl and benzenesulfonyl;
  • R 3 is selected from a hydrogen atom or an amino protecting group, preferably an amino protecting group, more preferably tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl and benzenesulfonyl.
  • Rw is bromine
  • R is selected from a hydrogen atom or a carboxyl protecting group, preferably a carboxyl protecting group, more preferably a C 1-6 alkyl group;
  • R is selected from a hydrogen atom or an amino protecting group, preferably an amino protecting group, more preferably tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl and benzenesulfonyl;
  • R 3 is selected from a hydrogen atom or an amino protecting group, preferably an amino protecting group, more preferably tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl and benzenesulfonyl.
  • R is phenyloxy
  • said phenyl is optionally substituted with one or more substituents selected from halogen, C 1-6 alkyl and C 1-6 alkoxy .
  • R 3 is an amino protecting group, the method further comprising
  • R 1 is as defined in formula (II).
  • the removal of the amino protecting group can be carried out by methods commonly used in the art, for example, according to different amino protecting groups, corresponding removal reagents can be used for deprotection.
  • the compound shown in formula (A') is prepared from the compound shown in formula (II) and the compound shown in formula (II-1) in the presence of a base, R 4 is a leaving group,
  • R 1 and R 2 are as defined in formula A'.
  • the molar ratio of the compound represented by formula (II) to the base is 1:0.1-1:10, preferably 1:1.5-1:5.
  • the base is selected from alkali metal carbonates, bicarbonates or hydroxides, preferably sodium carbonate, potassium carbonate or cesium carbonate.
  • the molar ratio of the compound represented by formula (II) to the compound represented by formula (II-1) is 1:0.1 to 1:10, preferably 1:1 to 1:5, more preferably 1:1 ⁇ 1:3.
  • the reaction temperature is -100 to -30°C, preferably -85 to -65°C.
  • the method also includes
  • R 6 is selected from C 1-6 alkyl.
  • R 3 is an amino protecting group, the method further comprising
  • the solvents used in the reactions described in the present disclosure can be conventional solvents such as dimethylformamide, 1-methyl-2-pyrrolidone, dimethyl sulfoxide, tetrahydrofuran, ethyl acetate, dioxane, toluene, One or more of dimethyl sulfoxide, diethyl ether, isopropyl ether, methyl tert-butyl ether, dichloromethane, chloroform, acetone, acetonitrile, methanol, ethanol, isopropanol, water, preferably tetrahydrofuran, ethyl acetate , dioxane, toluene, dimethyl sulfoxide, ether, isopropyl ether, dichloromethane, chloroform, acetone, acetonitrile, methanol, ethanol, isopropanol, one or more.
  • the compound represented by the formula (A') is selected from
  • the present disclosure also provides a method for preparing the compound represented by formula (A'G-1), comprising
  • the present disclosure also provides a method for preparing the compound represented by formula (A), comprising
  • R 3 ' is an amino protecting group
  • R 6 ' is a C 1-6 alkyl group.
  • the compound represented by the formula (A) is selected from
  • the present disclosure also provides a method for preparing the compound represented by formula (I), including the method for preparing the compound represented by formula (A') or the compound represented by formula (A) described in the present disclosure.
  • the compound represented by the formula (I) can be prepared by using the compound represented by the formula (A') or the compound represented by the formula (A) as a reactant by using the methods disclosed in the prior art, such as the methods disclosed in CN106573001A, WO2020038405, WO2019196915, etc. It is incorporated herein in its entirety.
  • the present disclosure also provides compounds represented by formula (III-K1),
  • R w ' is selected from or halogen, preferably or bromine
  • R 3 is selected from a hydrogen atom or an amino protecting group, preferably a hydrogen atom, tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl and benzenesulfonyl.
  • the present disclosure also provides compounds represented by formula (II'-K1),
  • R w ' is selected from or halogen, preferably or bromine
  • R is selected from a hydrogen atom or a carboxyl protecting group, preferably a carboxyl protecting group, more preferably a C 1-6 alkyl group;
  • R3 is selected from amino protecting groups, preferably tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyloxycarbonyl and benzenesulfonyl.
  • the present disclosure also provides compounds represented by formula (II-K1),
  • R w ' is selected from or halogen, preferably or bromine
  • R 1 is selected from a hydrogen atom or a carboxyl protecting group, preferably a carboxyl protecting group, more preferably a C 1-6 alkyl group.
  • alkyl in the present disclosure is preferably a C 1 -C 6 alkyl.
  • alkenyl in the present disclosure is preferably a C 2 -C 6 alkenyl.
  • alkynyl in the present disclosure is preferably a C 2 -C 6 alkynyl.
  • alkylene in the present disclosure is preferably a C 1 -C 6 alkylene.
  • alkenylene group described in the present disclosure is preferably a C 2 -C 6 alkenylene group.
  • alkynylene group described in the present disclosure is preferably a C 2 -C 6 alkynylene group.
  • alkoxy in the present disclosure is preferably C 1 -C 6 alkoxy.
  • alkylsulfide group described in the present disclosure is preferably a C 1 -C 6 alkylsulfide group.
  • cycloalkyl in the present disclosure is preferably 3 to 12 membered, more preferably 3 to 6 membered cycloalkyl.
  • fused cycloalkyl group is preferably 6 to 14 membered, more preferably 7 to 10 membered fused cycloalkyl group.
  • heterocyclic group described in the present disclosure is preferably a 3- to 12-membered heterocyclic group, more preferably a 3- to 6-membered heterocyclic group.
  • the "fused heterocyclic group" described in the present disclosure is preferably 6 to 14 membered, more preferably 7 to 10 membered condensed heterocyclic group.
  • aryl group described in the present disclosure is preferably a 6- to 14-membered aryl group, more preferably a 6- to 10-membered aryl group.
  • heteroaryl in the present disclosure is preferably 5 to 12 membered, more preferably 5 to 10 membered heteroaryl.
  • alkyl refers to a saturated aliphatic hydrocarbon group, which is a linear or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-Dimethylpropyl, 2,2-Dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylp
  • lower alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl Base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethyl Dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl group, 2,3-dimethylbutyl group, etc.
  • Alkyl groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, said substituents being preferably one or more of the following groups independently selected from alkyl radical, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy group, heterocycloalkoxy group, cycloalkylthio group, heterocycloalkylthio group, oxo group, carboxyl group or carboxylate group.
  • alkoxy refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl is as defined above.
  • alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
  • Alkoxy may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkoxy Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, Heterocycloalkylthio, carboxyl or carboxylate.
  • the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkoxy Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloal
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably containing 3 to 12 carbon atoms, more preferably containing 3 to 6 carbon atoms.
  • Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene Base, cyclooctyl, etc.; polycyclic cycloalkyl includes spiro ring, fused ring and bridged ring cycloalkyl. "Carbocycle” refers to the ring system in a cycloalkyl group.
  • heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent comprising 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), but excluding ring portions of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
  • ring atoms Preferably it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably it contains 3 to 6 ring atoms.
  • Non-limiting examples of monocyclic heterocyclyl groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidine group, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc., preferably piperidinyl and pyrrolidinyl.
  • Polycyclic heterocyclyls include spiro, fused and bridged heterocyclyls. "Heterocycle" refers to a ring system in a heterocyclyl group.
  • aryl refers to a 6 to 14 membered all-carbon monocyclic or fused polycyclic (that is, rings sharing adjacent pairs of carbon atoms) group, preferably 6 to 10 membered, having a conjugated pi-electron system, such as benzene base and naphthyl.
  • the aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring bonded to the parent structure is the aryl ring.
  • “Aromatic ring” refers to a ring system in an aryl group. Non-limiting examples of aryl groups include:
  • Aryl groups may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio, carboxyl or carboxylate, preferably phenyl.
  • heteroaryl refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen.
  • Heteroaryl is preferably 5 to 12 membered, such as imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazine group, etc., preferably imidazolyl, pyrazolyl, pyrimidinyl or thiazolyl; more preferably pyrazolyl or thiazolyl.
  • heteroaryl may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring bonded to the parent structure is a heteroaryl ring.
  • Heteroaryl refers to a ring system in a heteroaryl group.
  • Non-limiting examples of heteroaryl groups include:
  • Heteroaryl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , heterocycloalkylthio, carboxyl or carboxylate.
  • cycloalkyloxy refers to -O-cycloalkyl, which cycloalkyl is as defined above;
  • heterocyclyloxy refers to -O-heterocyclyl, which is as defined above;
  • aryloxy refers to -O-aryl, which is as defined above;
  • heteroaryloxy refers to -O-heteroaryl, which is as defined above;
  • Carboxyl protecting group is a suitable group known in the art for carboxyl protection, see the carboxyl protecting group in the literature ("Protective Groups in Organic Synthesis", 5 Th Ed. TW Greene & P. GM Wuts), as an example,
  • the carboxyl protecting group can be substituted or unsubstituted C 1-10 straight chain or branched chain alkyl, substituted or unsubstituted C 2-10 straight chain or branched alkenyl or alkynyl, substituted or unsubstituted Substituted C 3-8 cyclic alkyl, substituted or unsubstituted C 5-10 aryl or heteroaryl, or (C 1-8 alkyl or aryl) 3 silyl, etc.
  • amino-protecting group is a suitable group known in the art for amino-protection, referring to the amino-protecting group in the literature ("Protective Groups in Organic Synthesis", 5 Th.Ed.TW Greene & P.GM Wuts), preferably , the amino protecting group can be (C 1-10 alkyl or aryl) acyl, for example: formyl, acetyl, benzoyl, etc.; can be (C 1-6 alkyl or C 6-10 aryl base) sulfonyl; it can also be (C 1-6 alkoxy or C 6-10 aryloxy) carbonyl, for example: Boc or Cbz; it can also be substituted or unsubstituted alkyl, for example: trityl 2,4-dimethoxybenzyl (DMB), p-methoxybenzyl (PMB) or benzyl (Bn).
  • DMB trityl 2,4-dimethoxybenzyl
  • PMB
  • leaving group refers to an atom or functional group that breaks away from a larger molecule in a chemical reaction.
  • Representative leaving groups include halogen, substituted sulfonyloxy, phosphoryloxy, amino, (R j ) 3 N-, cyano, R j S-, etc., wherein R j is independently selected from hydrogen atom or C 1 -C 6 alkyl.
  • the substituted sulfonyloxy group may be C 1 -C 6 alkylsulfonyloxy, perfluoro C 1 -C 6 alkylsulfonyloxy, arylsulfonyloxy, aralkylsulfonyloxy and the like.
  • C 1 -C 6 alkylsulfonyloxy include C 1 -C 6 linear or branched alkylsulfonyloxy, such as methylsulfonyloxy, ethylsulfonyloxy, n-propyl ylsulfonyloxy, isopropylsulfonyloxy, n-butylsulfonyloxy, tert-butylsulfonyloxy, n-pentylsulfonyloxy and n-hexylsulfonyloxy.
  • perfluoro C 1 -C 6 alkylsulfonyloxy groups include C 1 -C 6 linear or branched perfluoroalkylsulfonyloxy groups, such as trifluoromethylsulfonyloxy, 1,1 ,2,2,2-pentafluoro-1-ethylsulfonyloxy, 1,1,2,2,3,3,3-heptafluoro-1-propylsulfonyloxy and 1,1,2 ,2,3,3,4,4,4-Nafluoro-1-butylsulfonyloxy.
  • arylsulfonyloxy examples include: optionally having 1 to 3 alkyl groups selected from C 1 to C 6 straight chain or branched chain, C 1 to C 6 straight chain or branched chain alkyl on the benzene ring; , phenylsulfonyloxy and naphthylsulfonyloxy substituents of the group consisting of nitro and halogen atoms.
  • phenylsulfonyloxy optionally having substituents include phenylsulfonyloxy, 4-methylphenylsulfonyloxy, 2-methylphenylsulfonyloxy, 4-nitro Phenylsulfonyloxy, 4-tolylsulfonyloxy, 2-nitrophenylsulfonyloxy, 3-chlorophenylsulfonyloxy and the like.
  • naphthylsulfonyloxy include ⁇ -naphthylsulfonyloxy, ⁇ -naphthylsulfonyloxy and the like.
  • aralkylsulfonyloxy groups include: phenyl (which optionally has 1 to 3 alkyl groups selected from C 1 to C 6 straight or branched chains, C 1 to C 6 straight chains on the benzene ring, chain or branched chain alkane, nitro and halogen atom substituents) substituted C 1 to C 6 straight chain or branched alkylsulfonyloxy; and C 1 to C 6 straight chain or branched by naphthyl Branched chain alkylsulfonyloxy.
  • alkylsulfonyloxy substituted by phenyl include benzylsulfonyloxy, 2-phenylethylsulfonyloxy, 4-phenylbutylsulfonyloxy, 4-methylbenzyl Sulfonyloxy, 2-methylbenzylsulfonyloxy, 4-nitrobenzylsulfonyloxy, 4-methylbenzylsulfonyloxy, 3-chlorobenzylsulfonyloxy and the like.
  • alkylsulfonyloxy group substituted with naphthyl examples include ⁇ -naphthylmethylsulfonyloxy, ⁇ -naphthylmethylsulfonyloxy and the like.
  • Optional or “optionally” means that the subsequently described event or circumstance can but need not occur, and that the description includes instances where the event or circumstance occurs or does not occur.
  • a heterocyclic group optionally substituted with an alkyl group means that an alkyl group may but need not be present, and the description includes cases where the heterocycle group is substituted with an alkyl group and cases where the heterocycle group is not substituted with an alkyl group .
  • the bond configuration is not specified, i.e. if there is configurational isomerism in the chemical structure, the bond can be or both Two configurations.
  • the bond If the configuration is not specified, it can be the Z configuration or the E configuration, or both configurations.
  • the known starting materials of the present disclosure can be adopted or synthesized according to methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Shaoyuan Chemical Technology (Accela ChemBio Inc), Darui chemical companies.
  • the reactions can all be carried out under an argon atmosphere or a nitrogen atmosphere.
  • the hydrogenation reaction is usually vacuumized and filled with hydrogen, and the operation is repeated 3 times.
  • the solution refers to an aqueous solution.
  • reaction temperature is room temperature, which is 20°C to 30°C.
  • reaction system was quenched by adding 5mL of water and then spin-dried directly.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

一种BTK抑制剂中间体的制备方法。具体涉及一种如式(A'K)所示化合物的制备方法，包括式(IIIK)所示化合物制备式(IIK)所示化合物的步骤，以及式(IIK)所示化合物制备式(A'K)所示化合物的步骤。该方法收率高、反应条件温和，适合工业化生产。

Description

一种BTK抑制剂中间体的制备方法
本申请要求申请日为2021年5月21日的中国专利申请2021105596779和申请日为2022年1月13日的中国专利申请2022100351464的优先权。本申请引用上述中国专利申请的全文。
技术领域
本公开属于医药领域，涉及一种BTK抑制剂中间体的制备方法。
背景技术
免疫细胞通常可以分为T细胞与B细胞两类，其中B细胞的主要职能是分泌各种抗体帮助人体抵御各种外来的侵入。Bruton酪氨酸蛋白激酶(BTK)是酪氨酸蛋白激酶亚家族的成员之一，属于Tec家族激酶，主要在B细胞中表达，分布于淋巴系统、造血及血液系统。B细胞受体(BCR)对于包括慢性淋巴细胞性白血病(CLL)和非霍奇金淋巴瘤的(NHL)亚型，套细胞淋巴瘤(MCL)，和弥漫性大B细胞淋巴瘤(DLBCL)在内的多种淋巴瘤的增殖及生存具有至关重要的调控作用，此外，B细胞在类风湿关节炎，系统性红斑狼疮，多发性硬化症，以及其他免疫疾病的发病机制中的作用已被临床证实。Bruton酪氨酸蛋白激酶(BTK)是BCR信号通路中的一个关键的蛋白激酶。能够调节正常B细胞的成熟、分化，也与多种B细胞淋巴组织失调疾病密切相关。因此，靶向小分子抑制剂BTK可对B细胞恶性肿瘤和自身免疫疾病的治疗提供效益。
WO2016007185A1涉及一种式(I)所示化合物，即(R)-4-氨基-1-(1-(丁-2-炔酰基)吡咯烷-3-基)-3-(4-(2,6-二氟苯氧基)苯基)-1,6-二氢-7H-吡咯并[2,3-d]哒嗪-7-酮，该化合物为新型BTK激酶抑制剂，在激酶选择性，临床疗效或适应症，及安全性等方面均有所改善，其结构如下所示：
Figure PCTCN2022094153-appb-000001
WO2016007185A1的还公开了式(A)所示的化合物，该化合物为制备式(I)化合物的重要中间体。式(A)所示的化合物的收率和纯度直接影响到后续化合物的产品质量。
Figure PCTCN2022094153-appb-000002
发明内容
本公开的目的在于提供一种新的BTK抑制剂中间体的制备方法。
本公开还提供了一种如式(A’K)所示化合物的制备方法，包括式(IIIK)所示化合物制备式(IIK)所示化合物的步骤，以及式(IIK)所示化合物制备式(A’K)所示化合物的步骤，
Figure PCTCN2022094153-appb-000003
其中：
R 1选自氢原子或羧基保护基，优选羧基保护基，更优选C 1-6烷基；
R 2选自氢原子或氨基保护基，优选氨基保护基，更优选叔丁基氧基羰基、9－芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基；
R 3选自氢原子或氨基保护基，优选氨基保护基，更优选叔丁基氧基羰基、9－芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基；
R w选自卤素、C 1-6烷基、C 1-6烷氧基、3至8元环烷基氧基、3至8元杂环基氧基、6至10元芳基氧基和5至10元杂芳基氧基，所述的C 1-6烷基、C 1-6烷氧基、3至8元环烷基氧基、3至8元杂环基氧基、6至10元芳基氧基和5至10元杂芳基氧基任选被选自卤素、C 1-6烷基和C 1-6烷氧基中的一个或多个取代基取代；
n选自0、1、2、3、4和5。
在某些实施方案中，本公开提供了一种如式(A’G)所示化合物的制备方法，包括式(IIIG)所示化合物制备式(IIG)所示化合物的步骤，以及式(IIG)所示化合物制备式(A’G)所示化合物的步骤，
Figure PCTCN2022094153-appb-000004
其中：
R 1选自氢原子或羧基保护基，优选羧基保护基，更优选C 1-6烷基；
R 2选自氢原子或氨基保护基，优选氨基保护基，更优选叔丁基氧基羰基、9－芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基；
R 3选自氢原子或氨基保护基，优选氨基保护基，更优选叔丁基氧基羰基、9－芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基；
R w选自卤素、C 1-6烷基、C 1-6烷氧基、3至8元环烷基氧基、3至8元杂环基氧基、6至10元芳基氧基和5至10元杂芳基氧基，所述的C 1-6烷基、C 1-6烷氧基、3至8元环烷基氧基、3至8元杂环基氧基、6至10元芳基氧基和5至10元杂芳基氧基任选被选自卤素、C 1-6烷基和C 1-6烷氧基中的一个或多个取代基取代。
在某些实施方案中，式(IIIK)所示化合物与式(III-1)所示化合物在碱试剂存在的条件下制备式(IIK)所示化合物，式(III-1)为
Figure PCTCN2022094153-appb-000005
X为卤素。
在某些实施方案中，式(IIIG)所示化合物与式(III-1)所示化合物在碱试剂存在的条件下制备式(IIG)所示化合物，式(III-1)为
Figure PCTCN2022094153-appb-000006
X为卤素。
在某些实施方案中，式(IIIK)所示化合物与式(III-1)所示化合物在碱试剂存在的条件下制备式(IIK)所示化合物，式(III-1)为
Figure PCTCN2022094153-appb-000007
X为卤素，所述碱试剂选自二异丙基氨基锂(LDA)、丁基锂、异丙基氯化镁等常见格式试剂。
在某些实施方案中，式(IIIG)所示化合物与式(III-1)所示化合物在碱试剂存在的条件下 制备式(IIG)所示化合物，式(III-1)为
Figure PCTCN2022094153-appb-000008
X为卤素，所述碱试剂选自二异丙基氨基锂(LDA)、丁基锂、异丙基氯化镁等常见格式试剂。
在某些实施方案中，X为氯。
在某些实施方案中，碱试剂为二异丙基氨基锂。本公开还提供了一种如式(A’)所示化合物的制备方法，包括式(III)所示化合物制备式(II)所示化合物的步骤，以及式(II)所示化合物制备式(A’)所示化合物的步骤，
Figure PCTCN2022094153-appb-000009
其中，R 1选自氢原子或羧基保护基，优选羧基保护基，更优选C 1-6烷基；
R 2选自氢原子或氨基保护基，优选氨基保护基，更优选叔丁基氧基羰基、9－芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基；
R 3选自氢原子或氨基保护基，优选氨基保护基，更优选叔丁基氧基羰基、9－芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基。
在某些实施方案中，式(III)所示化合物与式(III-1)所示化合物在碱试剂存在的条件下制备式(II)所示化合物，X为卤素，优选氯，所述碱试剂优选二异丙基氨基锂(LDA)、丁基锂、异丙基氯化镁等常见格式试剂，其中更优选二异丙基氨基锂。
Figure PCTCN2022094153-appb-000010
在某些实施方案中，所述的式(III)所示化合物与锂试剂的摩尔比为1:0.1～1:10，优选1:1～1:5，更优选1:1～1:3。
在某些实施方案中，所述的式(III)所示化合物与式(III-1)所示化合物的摩尔比为1:0.1～1:10，优选1:1～1:5，更优选1:1～1:3。
在某些实施方案中，反应温度-100～-30℃，优选-85～-65℃。
在某些实施方案中，R 3为氨基保护基，所述方法还包括
Figure PCTCN2022094153-appb-000011
其中：R 1、R w和n如式(IIK)中所定义。
在某些实施方案中，R 3为氨基保护基，所述方法还包括
Figure PCTCN2022094153-appb-000012
其中：R 1和R w如式(IIG)中所定义。
在某些实施方案中，其中R w为卤素或苯基氧基，所述苯基任选被选自卤素、C 1-6烷基和C 1-6烷氧基中的一个或多个取代基取代。
在某些实施方案中，提供一种制备式A’G的方法，其包括
Figure PCTCN2022094153-appb-000013
R w为卤素；
R 1选自氢原子或羧基保护基，优选羧基保护基，更优选C 1-6烷基；
R 2选自氢原子或氨基保护基，优选氨基保护基，更优选叔丁基氧基羰基、9－芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基；
R 3选自氢原子或氨基保护基，优选氨基保护基，更优选叔丁基氧基羰基、9－芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基。
在某些实施方案中，提供一种制备式A’G的方法，其包括
Figure PCTCN2022094153-appb-000014
其中R w为溴；
R 1选自氢原子或羧基保护基，优选羧基保护基，更优选C 1-6烷基；
R 2选自氢原子或氨基保护基，优选氨基保护基，更优选叔丁基氧基羰基、9－芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基；
R 3选自氢原子或氨基保护基，优选氨基保护基，更优选叔丁基氧基羰基、9－芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基。
在某些实施方案中，其中R w为苯基氧基，所述苯基任选被选自卤素、C 1-6烷基和C 1- 6烷氧基中的一个或多个取代基取代。
在某些实施方案中，R 3为氨基保护基，所述方法还包括
Figure PCTCN2022094153-appb-000015
R 1如式(II)中所定义。
脱除氨基保护基可采用本领域常用的方法，例如，根据不同的氨基保护基采取相应的脱除试剂脱保护。
在某些实施方案中，式(II)所示化合物与式(II-1)所示化合物在碱存在的条件下制备式(A’)所示化合物，R 4为离去基团，
Figure PCTCN2022094153-appb-000016
R 1和R 2如式A’中所定义。
在某些实施方案中，所述的式(II)所示化合物与碱的摩尔比为1:0.1～1:10，优选1:1.5～1:5。
在某些实施方案中，所述的碱选自碱金属的碳酸盐、碳酸氢盐或氢氧化物，优选碳酸钠、碳酸钾或碳酸铯。
在某些实施方案中，所述的式(II)所示化合物与式(II-1)所示化合物的摩尔比为1:0.1～1:10，优选1:1～1:5，更优选1:1～1:3。
在某些实施方案中，反应温度-100～-30℃，优选-85～-65℃。
在某些实施方案中，所述方法还包括
Figure PCTCN2022094153-appb-000017
其中，R 6选自C 1-6烷基。
在某些实施方案中，R 3为氨基保护基，所述方法还包括
Figure PCTCN2022094153-appb-000018
本公开所述的反应中使用的溶剂可以是常规溶剂，例如二甲基甲酰胺、1-甲基-2-吡咯烷酮、二甲基亚砜、四氢呋喃、乙酸乙酯、二氧六环、甲苯、二甲亚砜、乙醚、异丙醚、甲基叔丁基醚、二氯甲烷、氯仿、丙酮、乙腈、甲醇、乙醇、异丙醇、水中的一种或多种，优选四氢呋喃、乙酸乙酯、二氧六环、甲苯、二甲亚砜、乙醚、异丙醚、二氯甲烷、氯仿、丙酮、乙腈、甲醇、乙醇、异丙醇中的一种或多种。
在某些实施方案中，所述式(A’)所示化合物选自
Figure PCTCN2022094153-appb-000019
优选
Figure PCTCN2022094153-appb-000020
本公开还提供了一种制备式(A’G-1)所示化合物的方法，包括
Figure PCTCN2022094153-appb-000021
本公开还提供了一种制备式(A)所示化合物的方法，包括
Figure PCTCN2022094153-appb-000022
其中，R 3’为氨基保护基，R 6’为C 1-6烷基。
在某些实施方案中，所述式(A)所示化合物选自
Figure PCTCN2022094153-appb-000023
本公开还提供了一种制备式(I)所示化合物的方法，包括本公开所述的制备式(A’)所示化合物或式(A)所示化合物的方法。
另外，可采用现有技术公开的方法以式(A’)所示化合物或式(A)所示化合物为反应物制备式(I)所示化合物，例如CN106573001A、WO2020038405、WO2019196915等公开的方法，在此全文引入。
可选的方案包括，例如：
Figure PCTCN2022094153-appb-000024
本公开还提供了式(III-K1)所示化合物，
Figure PCTCN2022094153-appb-000025
其中，R w’选自
Figure PCTCN2022094153-appb-000026
或卤素，优选
Figure PCTCN2022094153-appb-000027
或溴，
R 3选自氢原子或氨基保护基，优选氢原子、叔丁基氧基羰基、9－芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基。
本公开还提供了式(II’-K1)所示化合物，
Figure PCTCN2022094153-appb-000028
其中，R w’选自
Figure PCTCN2022094153-appb-000029
或卤素，优选
Figure PCTCN2022094153-appb-000030
或溴，
R 1选自氢原子或羧基保护基，优选羧基保护基，更优选C 1-6烷基；
R 3选自氨基保护基，优选叔丁基氧基羰基、9－芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基。
本公开还提供了式(II-K1)所示化合物，
Figure PCTCN2022094153-appb-000031
其中，R w’选自
Figure PCTCN2022094153-appb-000032
或卤素，优选
Figure PCTCN2022094153-appb-000033
或溴，
R 1选自氢原子或羧基保护基，优选羧基保护基，更优选C 1-6烷基。
本公开所述的“烷基”优选C 1-C 6烷基。
本公开所述的“烯基”优选C 2-C 6烯基。
本公开所述的“炔基”优选C 2-C 6炔基。
本公开所述的“亚烷基”优选C 1-C 6亚烷基。
本公开所述的“亚链烯基”优选C 2-C 6亚链烯基。
本公开所述的“亚链炔基”优选C 2-C 6亚链炔基。
本公开所述的“烷氧基”优选C 1-C 6烷氧基。
本公开所述的“烷硫醚基”优选C 1-C 6烷硫醚基。
本公开所述的“环烷基”优选3至12元，更优选3至6元环烷基。
本公开所述的“稠环烷基”优选为6至14元，更优选为7至10元稠环烷基。
本公开所述的“杂环基”优选3至12元，更优选3至6元杂环基。
本公开所述的“稠杂环基”优选6至14元，更优选为7至10元稠杂环基。
本公开所述的“芳基”优选为6至14元，更优选为6至10元芳基。
本公开所述的“杂芳基”优选为5至12元，更优选为5至10元杂芳基。
除非有相反陈述，在说明书和权利要求书中使用的术语具有下述含义。
术语“烷基”指饱和脂肪族烃基团，其为包含1至20个碳原子的直链或支链基团，优选含有1至12个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基，及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基，非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的，当被取代时，取代基可以在任何可使用的连接点上被取代，所述取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基)，其中烷基的定义如上所述。烷氧基的非限制性实例包括：甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。烷氧基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“卤素”指氟、氯、溴或碘。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基，环烷基环包含3至20个碳原子，优选包含3至12个碳原子，更优选包含3至6个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等；多环环烷基包括螺环、稠环和桥环的环烷基。“碳环”指的是环烷基中的环系。
术语“杂环基”指饱和或部分不饱和单环或多环环状烃取代基，其包含3至20个环原子，其中一个或多个环原子为选自氮、氧或S(O) m(其中m是整数0至2)的杂原子，但不包括-O-O-、-O-S-或-S-S-的环部分，其余环原子为碳。优选包含3至12个环原子，其中1～4个是杂原子；更优选包含3至6个环原子。单环杂环基的非限制性实例包括吡咯烷基、咪唑烷基、四氢呋喃基、四氢噻吩基、二氢咪唑基、二氢呋喃基、二氢吡唑基、二氢吡咯基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基等，优选哌啶基、吡咯烷基。多环杂环基包括螺环、稠环和桥环的杂环基。“杂环”指的是杂环基中的环系。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团，优选为6至10元，例如苯基和萘基。所述芳基环可以稠合于杂芳基、杂环基或环烷基环上，其中与母体结构连接在一起的环为芳基环。“芳环”指的是芳基中的环系。芳基非限制性实例包括：
Figure PCTCN2022094153-appb-000034
芳基可以是取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基，优选苯基。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系，其中杂原子选自氧、硫和氮。杂芳基优选为5至12元，例如咪唑基、呋喃基、噻吩基、噻唑基、吡唑基、噁唑基、吡咯基、四唑基、吡啶基、嘧啶基、噻二唑、吡嗪基等，优选为咪唑基、吡唑基、嘧啶基或噻唑基；更优选为吡唑基或噻唑基。所述杂芳基环可以稠合于芳基、杂环基或环烷基环上，其中与母体结构连接在一起的环为杂芳基环。“杂芳环”指的是杂芳基中的环系。杂芳基非限制性实例包括：
Figure PCTCN2022094153-appb-000035
杂芳基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“环烷基氧基”指-O-环烷基，所述环烷基如上所定义；
术语“杂环基氧基”指-O-杂环基，所述杂环基如上所定义；
术语“芳基氧基”指-O-芳基，所述芳基如上所定义；
术语“杂芳基氧基”指-O-杂芳基，所述杂芳基如上所定义；
“羧基保护基”是本领域已知的适当的用于羧基保护的基团，参见文献(“Protective Groups in Organic Synthesis”，5 Th Ed.T.W.Greene&P.G.M.Wuts)中的羧基保护基团，作为示例，所述的羧基保护基可以是取代或非取代的C 1-10的直链或支链烷基、取代或非取代的C 2-10的直链或支链烯基或炔基、取代或非取代的C 3-8的环状烷基、取代或非取代的C 5-10的芳基或杂芳基、或(C 1-8烷基或芳基) 3硅烷基等。
“氨基保护基”是本领域已知的适当的用于氨基保护的基团，参见文献(“Protective Groups in Organic Synthesis”，5 Th.Ed.T.W.Greene&P.G.M.Wuts)中的氨基保护基团，优选地，所述的氨基保护基可以是(C 1-10烷基或芳香基)酰基，例如：甲酰基，乙酰基，苯甲酰基等；可以是(C 1-6烷基或C 6-10芳基)磺酰基；也可以是(C 1-6烷氧基或C 6-10芳基氧基)羰基，例如：Boc或Cbz；还可以是取代或非取代的烷基，例如：三苯甲基(Tr)、2,4-二甲氧基苄基(DMB)、对甲氧基苄基(PMB)或苄基(Bn)。
术语“离去基团”指在化学反应中从一较大分子中脱离的原子或官能基。具有代表性的离去基团有卤素、取代的磺酰基氧基、磷酰基氧基、氨基、(R j) 3N-、氰基、R jS-等，其中R j独立地选自氢原子或C 1～C 6烷基。
取代的磺酰基氧基可以是C 1～C 6烷基磺酰基氧基、全氟C 1～C 6烷基磺酰基氧基、芳基磺酰基氧基、芳烷基磺酰基氧基等。
C 1～C 6烷基磺酰基氧基的具体例子包括C 1～C 6直链或支链的烷基磺酰基氧基，例如甲 基磺酰基氧基、乙基磺酰基氧基、正丙基磺酰基氧基、异丙基磺酰基氧基、正丁基磺酰基氧基、叔丁基磺酰基氧基、正戊基磺酰基氧基和正己基磺酰基氧基。
全氟C 1～C 6烷基磺酰基氧基的具体例子包括C 1～C 6直链或支链的全氟烷基磺酰基氧基，例如三氟甲基磺酰基氧基、1,1,2,2,2-五氟-1-乙基磺酰基氧基、1,1,2,2,3,3,3-七氟-1-丙基磺酰基氧基和1,1,2,2,3,3,4,4,4-九氟-1-丁基磺酰基氧基。
芳基磺酰基氧基的例子包括：任选地在苯环上具有1至3个选自由C 1～C 6直链或支链的烷基、C 1～C 6直链或支链的烷、硝基和卤原子组成的组的取代基的苯基磺酰基氧基和萘基磺酰基氧基。任选地具有取代基的苯基磺酰基氧基的具体例子包括苯基磺酰基氧基、4-甲基苯基磺酰基氧基、2-甲基苯基磺酰基氧基、4-硝基苯基磺酰基氧基、4-甲苯基磺酰基氧基、2-硝基苯基磺酰基氧基、3-氯苯基磺酰基氧基等等。萘基磺酰基氧基的具体例子包括α-萘基磺酰基氧基、β-萘基磺酰基氧基等等。
芳烷基磺酰基氧基的例子包括：被苯基(其任选地在苯环上具有1至3个选自C 1～C 6直链或支链的烷基、C 1～C 6直链或支链的烷、硝基和卤原子的取代基)取代的C 1～C 6直链或支链的烷基磺酰基氧基；和被萘基取代的C 1～C 6直链或支链的烷基磺酰基氧基。被苯基取代的烷基磺酰基氧基的具体例子包括苄基磺酰基氧基、2-苯基乙基磺酰基氧基、4-苯基丁基磺酰基氧基、4-甲基苄基磺酰基氧基、2-甲基苄基磺酰基氧基、4-硝基苄基磺酰基氧基、4-甲苄基磺酰基氧基、3-氯苄基磺酰基氧基等等。被萘基取代的烷基磺酰基氧基的具体例子包括α-萘基甲基磺酰基氧基、β-萘基甲基磺酰基氧基等等。
“任选”或“任选地”意味着随后所描述地事件或环境可以但不必发生，该说明包括该事件或环境发生或不发生地场合。例如，“任选被烷基取代的杂环基团”意味着烷基可以但不必须存在，该说明包括杂环基团被烷基取代的情形和杂环基团不被烷基取代的情形。
本公开所述化合物的化学结构中，键
Figure PCTCN2022094153-appb-000036
并未指定构型，即如果化学结构中存在构型异构，键
Figure PCTCN2022094153-appb-000037
可以为
Figure PCTCN2022094153-appb-000038
或者同时包含
Figure PCTCN2022094153-appb-000039
两种构型。本公开所述化合物的化学结构中，键
Figure PCTCN2022094153-appb-000040
并未指定构型，即可以为Z构型或E构型，或者同时包含两种构型。
具体实施方式
以下将结合具体实例详细地解释本公开，使得本专业技术人员更全面地理解本公开具体实例仅用于说明本公开的技术方案，并不以任何方式限定本公开。
本公开的已知的起始原料可以采用或按照本领域已知的方法来合成，或可购买自 ABCR GmbH&Co.KG，Acros Organics，Aldrich Chemical Company，韶远化学科技(Accela ChemBio Inc)、达瑞化学品等公司。
实施例中无特殊说明，反应能够均在氩气氛或氮气氛下进行。
氢化反应通常抽真空，充入氢气，反复操作3次。
实施例中无特殊说明，溶液是指水溶液。
实施例中无特殊说明，反应的温度为室温，为20℃～30℃。
实施例1
Figure PCTCN2022094153-appb-000041
步骤1：化合物1的合成
将25g的2,6-二氟苯酚加入到250ml DMF中，加入碳酸钾79g，对氟苯甲醛28.6g，加热到110℃，搅拌反应至完全，加入冰水，过滤，滤饼用纯化水洗涤，干燥后用乙酸乙酯正己烷打浆，得到化合物1共38g，收率85％，HPLC纯度:98.7％。
1HNMR(400MHz,DMSO-d 6):δ9.93(s,1H),7.95(d,2H,J＝8.8Hz),7.45-7.37(m,3H),7.15(d,2H,J＝8.8Hz),
步骤2：化合物2的合成
化合物1(20g)溶于200ml乙醇中，加入醋酸铵1.32g和氰基乙酸乙酯10.14g，加热到60℃搅拌至反应完全。冷却至室温，缓慢加入水，过滤，滤饼用乙醇和纯化水混合溶剂洗涤(EtOH:H 2O＝1:2)洗涤，干燥得化合物2共28.7g，收率100％，HPLC纯度:98.4％。
1HNMR(400MHz,DMSO-d 6):δ8.374(s,1H),8.14(d,2H,J＝8.8Hz),7.46-7.34(m,3H),7.19(d,2H,J＝8.8Hz),4.32(q,2H,J＝7.2Hz),1.310(t,3H,J＝7.2Hz)
步骤3：化合物3的合成
将28.7g化合物2溶于200mL乙醇中，冰浴下，加入乙醇钠溶液35.6g(20％)。将化合物2-1(18.7g)加入反应体系，搅拌反应至反应完全，加入氯化铵溶液洗涤，加入乙酸乙酯分层，有机相用饱和食盐水洗涤，干燥，浓缩得到粗品，粗品用DCM:PE＝1:6重结晶，得23.3g化合物3，收率91％，HPLC纯度:99.19％。
1HNMR(400MHz,DMSOd 6):δ11.91(s,1H),7.70(d,1H,J＝2.0Hz),7.69(d,2H,J＝8.4Hz),7.61-7.30(m,3H),7.26(d,1H,J＝2.0Hz),7.13(d,2H,J＝8.4Hz)
步骤4：化合物4的合成
将23.2g化合物3溶于230mL二氯甲烷中，加入2eq三乙胺和0.1eq DMAP，降温至0℃，滴加1.1eq苯磺酰氯。保持该温度搅拌至反应完全。依次加入纯化水、稀盐酸和碳酸氢钠、食盐水洗涤，无水硫酸钠干燥，过滤浓缩后得到粗品。粗品用PE:EA＝10:1打浆，干燥得到化合物4共30.6g，收率90％，HPLC纯度:99.80％。
1HNMR(400MHz,DMSOd 6):δ8.50(s,1H),8.15(dd,2H,J＝6.8Hz,3.2Hz),7.93(d,1H,J＝3.2Hz),7.75(m,1H),7.65-7.62(m,4H),7.42(m,3H),7.04(d,2H,J＝8.8Hz)
步骤5：化合物5的合成
将220ml四氢呋喃加入反应瓶，降温至-70℃，滴加1.5eq的LDA(2M in THF)至反应瓶中，缓慢滴加化合物3(22g)的四氢呋喃溶液50mL，保持-70℃搅拌1h，之后缓慢滴加2.0eq氯甲酸乙酯至反应瓶中，保持-70℃搅拌1h，自然升至室温，搅拌至反应完全后，加入氯化铵淬灭，乙酸乙酯萃取，食盐水洗涤，干燥，浓缩得到粗品，粗品用PE:EA＝10:1打浆，得到化合物5共23.2g，收率90.6％，HPLC纯度:98.97％。
1HNMR(400MHz,DMSOd 6):δ8.32(s,1H),8.20(d,2H,J＝8.8Hz),7.85(m,1H),7.77-7.72(m,4H),7.44-7.33(m,3H),7.15(d,2H,J＝8.8Hz),4.34(q,1H,J＝7.2Hz),1.27(t,3H,J＝7.2Hz)
步骤6：化合物6的合成
23g化合物5使用200mL四氢呋喃溶解，加入1.1eq TBAF，加热到70℃，搅拌至反应完全，加入纯化水洗涤，乙酸乙酯萃取，有机相用碳酸氢钠、稀盐酸和氯化钠洗涤，有机相干燥，过滤，浓缩得到粗品。粗品用PE:EA＝10:1打浆后得到化合物6共15.0g，收率90％,HPLC纯度:99.32％。
1H NMR(400MHz,DMSOd 6):δ13.01(s,1H),7.70(2H,dd,J＝7.8Hz,3.2Hz),7.65(1H,s),7.54-7.32(m,3H),7.05(2H,dd,J＝7.8Hz,3.2Hz),4.35(q,1H,J＝7.2Hz),1.34(t,3H,J＝7.2Hz)
步骤7：化合物A1的合成
将10g化合物6溶解于100mL DMF中，加入1.5eq化合物6-1和3eq碳酸铯，氮气保护，加热到80℃搅拌至反应完全，加入水、乙酸乙酯分层，有机相用氯化铵、食盐水洗涤。有机相分层后干燥，浓缩得到粗品。粗品加入2V的无水乙醇加热溶清，过滤掉不溶物，降温至室温，加入晶种，搅拌析晶过夜，得到高纯度的化合物A1共11.6g，收率80％,HPLC纯度:99.94％。
1H NMR(400MHz,DMSOd 6):δ7.72-7.62(m,3H),7.42-7.31(m,3H),7.06(d,1H,J＝7.2Hz)5.62(m,1H),4.37(q,1H,J＝7.2Hz),3.79(m,1H),3.50(m,1H),3.42(m,1H),2.51-2.36(m,1H)
1.40-1.33(m,12H)
实施例2
Figure PCTCN2022094153-appb-000042
步骤1：式(II’G-1)化合物的合成
将40g式(IIIG-1)化合物溶于900mL四氢呋喃中，冷却至-80℃，缓慢滴加77mL  LDA溶液(2M)，滴加完毕后保温反应1h。滴加22.4g氯甲酸乙酯，滴完后低温反应2h后缓慢升至室温反应，TLC监测反应完全。
反应体系以20mL饱和氯化铵溶液淬灭，加入1L乙酸乙酯萃取，水洗，氯化钠溶液洗涤，干燥旋干后粗品以PE/EA＝10/1打浆，真空干燥得式(II’G-1)化合物，类白色固体41.0g，收率86.4％。
式(II’G-1)化合物: 1HNMR(400MHz，CDCl 3),8.08(m,2H),7.81(s,1H),7.71(m,1H),7.60(m,4H),7.49(m,2H),4.38(q,J＝7.2Hz,2H),1.39(t,J＝7.2Hz,3H)。
步骤2：式(IIG-1)化合物的合成
将40g式(II’G-1)化合物溶于300mL四氢呋喃中，滴加95mL TBAF溶液(1M)，升温至70℃反应2h。TLC监测反应完全。
反应体系加入300mL乙酸乙酯萃取，水洗，氯化钠溶液洗涤，干燥旋干后粗品以PE/EA＝10/1打浆，真空干燥得式(IIG-1)化合物，灰色固体27.7g，收率100％。
式(III-1)化合物: 1HNMR(400MHz，CDCl 3),8.77(brs,1H),7.51(m,4H),7.17(s,1H),4.44(q,J＝7.2Hz,2H),1.43(t,J＝7.2Hz,3H)。
步骤3：式(A’G-1)化合物的合成
将8g式(IIG-1)化合物，8.1g三苯基膦，5.8g(S)-1-N-叔丁氧羰基-3-羟基吡咯烷溶于200mL四氢呋喃中，冰浴降温至0℃左右，控温0-5℃滴加5.4g DEAD，保持低温反应2h。TLC监测反应完全。
反应体系加入5mL水淬灭后直接旋干，粗品以PE/Acetone＝5/1柱层析，浓缩即得式(A’G-1)化合物，白色泡沫状固体11.2g，收率92％。
式(II-1)化合物: 1HNMR(400MHz，DMSO-d 6),7.79(m,1H),7.67(m,4H),5.62(m,1H),4.35(m 2H),3.79(m,1H),3.49(m,3H),3.38(m,2H),2.39(m,2H),1.38(m,12H)。
由于已根据其特殊的实施方案描述了本公开，某些修饰和等价变化对于精通此领域的技术人员是显而易见的且包括在本公开的范围内。

Claims (24)

  1. 一种如式(A’K)所示化合物的制备方法，包括式(IIIK)所示化合物制备式(IIK)所示化合物的步骤，以及式(IIK)所示化合物制备式(A’K)所示化合物的步骤，
    Figure PCTCN2022094153-appb-100001
    其中：
    R 1选自氢原子或羧基保护基，优选羧基保护基，更优选C 1-6烷基；
    R 2选自氢原子或氨基保护基，优选氨基保护基，更优选叔丁基氧基羰基、9-芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基；
    R 3选自氢原子或氨基保护基，优选氨基保护基，更优选叔丁基氧基羰基、9-芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基；
    R w选自卤素、C 1-6烷基、C 1-6烷氧基、3至8元环烷基氧基、3至8元杂环基氧基、6至10元芳基氧基和5至10元杂芳基氧基，所述的C 1-6烷基、C 1-6烷氧基、3至8元环烷基氧基、3至8元杂环基氧基、6至10元芳基氧基和5至10元杂芳基氧基任选被选自卤素、C 1-6烷基和C 1-6烷氧基中的一个或多个取代基取代；
    n选自0、1、2、3、4和5。
  2. 根据权利要求1所述的制备方法，其中式(A’K)所示的化合物为式(A’)所示化合物，
    Figure PCTCN2022094153-appb-100002
    式(A’)所示化合物的制备方法包括式(III)所示化合物制备式(II)所示化合物的步骤，以及式(II)所示化合物制备式(A’)所示化合物的步骤，
    Figure PCTCN2022094153-appb-100003
    其中，R 1、R 2和R 3如权利要求1中所定义。
  3. 根据权利要求2所述的制备方法，其中式(III)所示化合物与式(III-1)所示化合物在碱试剂存在的条件下制备式(II)所示化合物，所述碱试剂优选二异丙基氨基锂、丁基锂或格式试剂，更优选二异丙基氨基锂；
    Figure PCTCN2022094153-appb-100004
    其中，X为卤素，优选氯；
    其中，R 1和R 3如权利要求1中所定义。
  4. 根据权利要求3所述的制备方法，其中所述的式(III)所示化合物与锂试剂的摩尔比为1:0.1～1:10，优选1:1～1:5，更优选1:1～1:3。
  5. 根据权利要求3或4所述的制备方法，其中所述的式(III)所示化合物与式(III-1)所示化合物的摩尔比为1:0.1～1:10，优选1:1～1:5，更优选1:1～1:3。
  6. 根据权利要求1所述的制备方法，其中R 3为氨基保护基，所述方法包括
    Figure PCTCN2022094153-appb-100005
    其中：R 1、R w和n如权利要求1中所定义。
  7. 根据权利要求1或6所述的制备方法，其中R w为卤素或苯基氧基，所述苯基任选被选自卤素、C 1-6烷基和C 1-6烷氧基中的一个或多个取代基取代。
  8. 根据权利要求7所述的制备方法，其包括：
    Figure PCTCN2022094153-appb-100006
    R w为卤素，优选地，R w为溴；
    R 1、R 2和R 3如权利要求1中所定义。
  9. 根据权利要求7所述的制备方法，其中R w为苯基氧基，所述苯基任选被选自卤素、C 1-6烷基和C 1-6烷氧基中的一个或多个取代基取代。
  10. 根据权利要求1-6任意一项所述的制备方法，其中R 3为氨基保护基，所述方法包括
    Figure PCTCN2022094153-appb-100007
    R 1如权利要求1或2中所定义。
  11. 根据权利要求1-10任意一项所述的制备方法，其中式(II)所示化合物与式(II-1)所示化合物在碱存在的条件下制备式(A’)所示化合物，R 4为离去基团，
    Figure PCTCN2022094153-appb-100008
    R 1和R 2如权利要求1或2中所定义。
  12. 根据权利要求11所述的制备方法，其中所述的式(II)所示化合物与碱的摩尔比为1:0.1～1:10，优选1:1.5～1:5。
  13. 根据权利要求11或12所述的制备方法，其中所述的碱选自碱金属的碳酸盐、碳酸氢盐或氢氧化物，优选碳酸钠、碳酸钾或碳酸铯。
  14. 根据权利要求11-13任意一项所述的制备方法，其中所述的式(II)所示化合物与式(II-1)所示化合物的摩尔比为1:0.1～1:10，优选1:1～1:5，更优选1:1～1:3。
  15. 根据权利要求1-14任意一项所述的制备方法，其中所述方法还包括：
    Figure PCTCN2022094153-appb-100009
    其中，R 6选自C 1-6烷基，R 3如权利要求1或2中所定义。
  16. 根据权利要求15所述的制备方法，其中R 3为氨基保护基，所述方法还包括
    Figure PCTCN2022094153-appb-100010
    其中：R 6如权利要求15中所定义。
  17. 根据权利要求1-16任意一项所述的制备方法，其中所述式(A’)所示化合物选自
    Figure PCTCN2022094153-appb-100011
    优选
    Figure PCTCN2022094153-appb-100012
  18. 一种制备式(A’G-1)所示化合物的方法，包括
    Figure PCTCN2022094153-appb-100013
  19. 一种制备式(A)所示化合物的方法，包括
    Figure PCTCN2022094153-appb-100014
    其中，R 3’为氨基保护基，R 6’为C 1-6烷基。
  20. 一种制备式(I)所示化合物或其可药用盐的方法，包括权利要求1-19任意一项所述的制备式(A’)所示化合物或式(A)所示化合物的步骤，
    Figure PCTCN2022094153-appb-100015
  21. 根据权利要求20所述的制备方法，所述方法还包括
    Figure PCTCN2022094153-appb-100016
  22. 式(III-K1)所示化合物，
    Figure PCTCN2022094153-appb-100017
    其中，R w’选自
    Figure PCTCN2022094153-appb-100018
    或卤素，优选
    Figure PCTCN2022094153-appb-100019
    或溴，
    R 3选自氢原子或氨基保护基，优选氢原子、叔丁基氧基羰基、9-芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基。
  23. 式(II’-K1)所示化合物，
    Figure PCTCN2022094153-appb-100020
    其中，R w’选自
    Figure PCTCN2022094153-appb-100021
    或卤素，优选
    Figure PCTCN2022094153-appb-100022
    或溴，
    R 1选自氢原子或羧基保护基，优选羧基保护基，更优选C 1-6烷基；
    R 3选自氨基保护基，优选叔丁基氧基羰基、9-芴基甲基氧基羰基、苄基氧基羰基和苯磺酰基。
  24. 式(II-K1)所示化合物，
    Figure PCTCN2022094153-appb-100023
    其中，R w’选自
    Figure PCTCN2022094153-appb-100024
    或卤素，优选
    Figure PCTCN2022094153-appb-100025
    或溴，
    R 1选自氢原子或羧基保护基，优选羧基保护基，更优选C 1-6烷基。
PCT/CN2022/094153 2021-05-21 2022-05-20 一种btk抑制剂中间体的制备方法 WO2022242752A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280036495.6A CN117355513A (zh) 2021-05-21 2022-05-20 一种btk抑制剂中间体的制备方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110559677 2021-05-21
CN202110559677.9 2021-05-21
CN202210035146 2022-01-13
CN202210035146.4 2022-01-13

Publications (1)

Publication Number Publication Date
WO2022242752A1 true WO2022242752A1 (zh) 2022-11-24

Family

ID=84141122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/094153 WO2022242752A1 (zh) 2021-05-21 2022-05-20 一种btk抑制剂中间体的制备方法

Country Status (3)

Country Link
CN (1) CN117355513A (zh)
TW (1) TW202313568A (zh)
WO (1) WO2022242752A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679244A (zh) * 2007-04-11 2010-03-24 橘生药品工业株式会社 5元杂环衍生物及其医药用途
WO2010093191A2 (en) * 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
CN102516149A (zh) * 2011-11-09 2012-06-27 上海交通大学 1，3，4-三取代吡咯类化合物及其制备方法和应用
WO2016007185A1 (en) * 2014-07-07 2016-01-14 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
WO2018121228A1 (zh) * 2016-12-28 2018-07-05 中国科学院上海药物研究所 一种具有axl抑制活性的化合物及其制备和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679244A (zh) * 2007-04-11 2010-03-24 橘生药品工业株式会社 5元杂环衍生物及其医药用途
WO2010093191A2 (en) * 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
CN102516149A (zh) * 2011-11-09 2012-06-27 上海交通大学 1，3，4-三取代吡咯类化合物及其制备方法和应用
WO2016007185A1 (en) * 2014-07-07 2016-01-14 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
WO2018121228A1 (zh) * 2016-12-28 2018-07-05 中国科学院上海药物研究所 一种具有axl抑制活性的化合物及其制备和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOLLET J-F,ET AL: "Synthesis and phloem mobility of acidic derivatives of the fungicide fenpiclonil", PEST MANAGEMENT SCIENCE, PUBLISHED FOR SCI BY WILEY, vol. 60, 15 June 2004 (2004-06-15), pages 1063 - 1072, XP002367075, ISSN: 1526-498X, DOI: 10.1002/ps.906 *
DATABASE REGISTRY 30 August 2017 (2017-08-30), "1H-Pyrrole-3-carbonitrile, 1-ethyl-4-(4-fluorophenyl)", XP093006043, retrieved from STN Database accession no. RN -2122495-38-7 *

Also Published As

Publication number Publication date
TW202313568A (zh) 2023-04-01
CN117355513A (zh) 2024-01-05

Similar Documents

Publication Publication Date Title
DE69310501T2 (de) Chinolylbenzofuran derivate als leukotrien-antagonisten
CN108047261B (zh) 一种克立硼罗的制备方法
ES2380443T3 (es) Proceso para la producción de ácido 1-(3-(2-(1-benzotiofen-5-il)etoxi)propiónico o sales del mismo
JP2600644B2 (ja) チアゾリルベンゾフラン誘導体
JP5148507B2 (ja) Ｇａｂａａ受容体調節物質としての置換シンノリン誘導体及びその合成法
US7465795B2 (en) Compounds and uses thereof
KR20090090386A (ko) 벤즈이미다졸 ｔｒｐｖ1 저해제
CN114685460A (zh) Kras g12c抑制剂及其在医药上的应用
WO2022194066A1 (zh) Kras g12d抑制剂及其在医药上的应用
TW202220976A (zh) Cd73抑制劑及其在醫藥上的應用
CA3104956C (en) Novel lxr modulators with bicyclic core moiety
CN106146518A (zh) 一种布鲁顿酪氨酸激酶抑制剂中间体及其制备方法
WO2022242752A1 (zh) 一种btk抑制剂中间体的制备方法
WO2021057998A1 (zh) 一种吡咯并氨基哒嗪酮化合物的制备方法
TW202019904A (zh) 一種凝血因子ＸＩａ抑制劑及其中間體的製備方法
EP0276500B1 (en) 2-oxindole intermediates
JPS59170090A (ja) インド−ル誘導体
CN103570698B (zh) 用于制备维拉佐酮的化合物及其中间体和应用
RU2397169C2 (ru) Способ получения 1-(3-(2-(1-бензотиофен-5-ил)этокси) пропил)азетидин-3-ола или его солей
TWI691495B (zh) 一種酪胺酸激酶抑制劑及其中間體的製備方法
CN108017522B (zh) 一种2,6-二溴苯甲磺酰氯的制备工艺
TWI851921B (zh) 吡嗪類衍生物及其在抑制shp2中的應用
Brañ et al. Synthesis of 4-(4-pyridyl) oxazoles
CN116425664A (zh) 一种杂芳环类btk抑制剂中间体的制备方法
CN114560805A (zh) 含氮杂环化合物及其中间体的合成方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22804071

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280036495.6

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22804071

Country of ref document: EP

Kind code of ref document: A1